PURPOSE: The purpose of this study was to evaluate if sequential 99mTc Hynic-rh- annexin V scintigraphy (TAS) can predict outcome in patients with advanced lung cancer, shortly after the start of platinum-based chemotherapy. PATIENTS AND METHODS: In 16 consecutive chemotherapy-naive patients with advanced stage non-small-cell lung cancer scheduled for platinum-based chemotherapy, TAS was performed before and within 48 hours after the start of therapy. Chemotherapy-induced changes in tumor annexin V uptake, calculated as maximum count per pixel and expressed as percentage to baseline value, were compared with treatment response determined according to Response Evaluation Criteria in Solid Tumors. RESULTS: A significant correlation (r2 = 0.86; P = .0001) was found between annexin V metabolic changes and treatment outcome. All patients with notably increased annexin V tumor uptake showed complete or partial response. Less prominently increased or decreased uptake correlated with stable or progressive disease. CONCLUSION: TAS is a promising test to predict tumor response in patients with advanced lung cancer early in the course of platinum-based chemotherapy.
PURPOSE: The purpose of this study was to evaluate if sequential 99mTc Hynic-rh- annexin V scintigraphy (TAS) can predict outcome in patients with advanced lung cancer, shortly after the start of platinum-based chemotherapy. PATIENTS AND METHODS: In 16 consecutive chemotherapy-naive patients with advanced stage non-small-cell lung cancer scheduled for platinum-based chemotherapy, TAS was performed before and within 48 hours after the start of therapy. Chemotherapy-induced changes in tumorannexin V uptake, calculated as maximum count per pixel and expressed as percentage to baseline value, were compared with treatment response determined according to Response Evaluation Criteria in Solid Tumors. RESULTS: A significant correlation (r2 = 0.86; P = .0001) was found between annexin V metabolic changes and treatment outcome. All patients with notably increased annexin Vtumor uptake showed complete or partial response. Less prominently increased or decreased uptake correlated with stable or progressive disease. CONCLUSION:TAS is a promising test to predict tumor response in patients with advanced lung cancer early in the course of platinum-based chemotherapy.
Authors: Tarik Z Belhocine; Francis G Blankenberg; Marina S Kartachova; Larry W Stitt; Jean-Luc Vanderheyden; Frank J P Hoebers; Christophe Van de Wiele Journal: Eur J Nucl Med Mol Imaging Date: 2015-08-16 Impact factor: 9.236
Authors: Hossein Nejadnik; Deju Ye; Olga D Lenkov; Jessica S Donig; John E Martin; Rostislav Castillo; Nikita Derugin; Barbara Sennino; Jianghong Rao; Heike Daldrup-Link Journal: ACS Nano Date: 2015-01-26 Impact factor: 15.881